Navigating the maze: Establishing novel endpoints for IRD trials

In this article with Modern Retina, our Chief Medical Officer, David J. Tanzer, MD, ABO, joins Daniel Chung, DO, MA from Beacon Therapeutics, as well as Huma Qumar, MD, MPH, and Murthy Chavali, PhD from Ocugen, to discuss functional endpoints for Inherited Retinal Disease (IRD) trials. They delve into breakthrough cases, the unique challenges of IRD drug development, real-world vs. virtual assessments, and key regulatory considerations.

Our Visionary Insights newsletter is published once a month and has thousands of subscribers. To stay in touch, subscribe today.